Plain-English translation of NCT06263959 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new medication called to see if it can help people with chronic hepatitis B who are already on stable antiviral therapy. Researchers want to understand whether taking this new tablet is safe and whether it helps improve virus control in your body. About 45 people will participate, and some will receive the medication while others receive a placebo (a pill with no active ingredient) so researchers can fairly measure how well the treatment works.
People with chronic hepatitis B who take standard antiviral medications can control their virus, but many still have detectable levels of hepatitis B virus in their blood. This trial exists to see whether adding this new treatment could help achieve even better virus suppression and potentially lead to better long-term health outcomes.
You likely qualify if…
You likely don't qualify if…
You will continue taking your current hepatitis B medications as usual. Depending on which group you are assigned to, you will also take the study medication (or placebo) by mouth for either 28 days or 12 weeks. Throughout the study, you will have regular clinic visits for blood tests and check-ups to monitor your safety and how well the medication works. The study uses a randomized, double-blind design, meaning you won't know whether you're receiving the active medication or placebo, and neither will the research team — this helps ensure fair and unbiased results.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Fujian Akeylink Biotechnology Co., Ltd.
Enrollment target
~45 participants
Started
December 2023
Primary completion
April 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
35 Years – 65 Years
Last updated on clinicaltrials.gov in March 2025.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.